139 related articles for article (PubMed ID: 36054998)
1. Molecular subtyping for lung adenocarcinoma and a novel prognostic model based on ligand-receptor pairs.
Li D; Ma X; Ou S
Adv Med Sci; 2022 Sep; 67(2):316-327. PubMed ID: 36054998
[TBL] [Abstract][Full Text] [Related]
2. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma.
Jie Y; Wu J; An D; Li M; He H; Wang D; Gu A; E M
Front Pharmacol; 2023; 14():1099927. PubMed ID: 36726580
[No Abstract] [Full Text] [Related]
5. Intercellular Communication-Related Molecular Subtypes and a Gene Signature Identified by the Single-Cell RNA Sequencing Combined with a Transcriptomic Analysis.
Guan P; Cai W; Wu K; Jiang F; Wu J; Zhai X; Zeng M
Dis Markers; 2022; 2022():6837849. PubMed ID: 35620271
[TBL] [Abstract][Full Text] [Related]
6. Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma.
Guo Z; Hu L; Wang Q; Wang Y; Liu XP; Chen C; Li S; Hu W
Curr Oncol; 2023 Feb; 30(3):2845-2861. PubMed ID: 36975430
[TBL] [Abstract][Full Text] [Related]
7. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
8. Constructing novel molecular subtypes and an 11-gene signature based on pyroptosis signaling for lung adenocarcinoma.
Li L; He Q; Tao Z; Zhang R; Cui Y; Qian L
Am J Cancer Res; 2022; 12(7):3051-3066. PubMed ID: 35968341
[TBL] [Abstract][Full Text] [Related]
9. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
[TBL] [Abstract][Full Text] [Related]
10. Identification of natural killer cell associated subtyping and gene signature to predict prognosis and drug sensitivity of lung adenocarcinoma.
Zhang D; Zhao Y
Front Genet; 2023; 14():1156230. PubMed ID: 37091780
[No Abstract] [Full Text] [Related]
11. Identification of Prognostic and Immune Characteristics of Two Lung Adenocarcinoma Subtypes Based on TRPV Channel Family Genes.
Jiang J; Zheng P; Li L
J Membr Biol; 2024 Apr; 257(1-2):115-129. PubMed ID: 38150051
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of ligand-receptor interactions in colon adenocarcinoma to identify of tumor microenvironment oxidative stress and prognosis model.
Hu J; Zhu W; Wang W; Yue X; Zhao P; Kong D
Curr Med Chem; 2023 Aug; ():. PubMed ID: 37605402
[TBL] [Abstract][Full Text] [Related]
14. LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response.
Huang J; Yuan L; Huang W; Liao L; Zhu X; Wang X; Li J; Liang W; Wu Y; Liu X; Yu D; Zheng Y; Guan J; Zhan Y; Liu L
Front Immunol; 2022; 13():1064874. PubMed ID: 36505456
[TBL] [Abstract][Full Text] [Related]
15. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
[TBL] [Abstract][Full Text] [Related]
16. Single-cell and Bulk RNA-Seq reveal angiogenic heterogeneity and microenvironmental features to evaluate prognosis and therapeutic response in lung adenocarcinoma.
Tang L; Chen Z; Yang J; Li Q; Wang S; Mo T; Zeng W; Ding H; Pan S
Front Immunol; 2024; 15():1352893. PubMed ID: 38390340
[TBL] [Abstract][Full Text] [Related]
17. Identifying Molecular Subtypes and 6-Gene Prognostic Signature Based on Hypoxia for Optimizing Targeted Therapies in Non-Small Cell Lung Cancer.
Lin J; Chen S; Xiao L; Wang Z; Lin Y; Xu S
Int J Gen Med; 2022; 15():4417-4432. PubMed ID: 35509605
[TBL] [Abstract][Full Text] [Related]
18. Characterization of molecular subtypes based on chromatin regulators and identification of the role of NPAS2 in lung adenocarcinoma.
Huang Y; Xiao L; Daba MY; Xu D; Wang Y; Li L; Li Q; Liu B; Qin W; Zhang H; Yuan X
Clin Epigenetics; 2023 Apr; 15(1):72. PubMed ID: 37120564
[TBL] [Abstract][Full Text] [Related]
19. Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma.
Chen Z; Yang X; Bi G; Liang J; Hu Z; Zhao M; Li M; Lu T; Zheng Y; Sui Q; Yang Y; Zhan C; Jiang W; Wang Q; Tan L
Int J Biol Sci; 2020; 16(12):2205-2219. PubMed ID: 32549766
[No Abstract] [Full Text] [Related]
20. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
